🔎 Trials Near Me

Home › Overactive Bladder › NCT07425015

Ambulatory Long Length URodynamics Evaluation

Recruiting

Who can join

Ages 22 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

1. Male or female patient must be ≥ 22 years of age.
2. Patient is a candidate for UDS per standard of care.
3. Patient is able to provide informed consent.

Exclusion Criteria:

1. Patient has one or more symptoms indicative of a urinary tract infection (UTI) (i.e., fever, costovertebral angle pain or tenderness, suprapubic tenderness, worsening urinary frequency, worsening urgency, and/or dysuria).
2. Patient has a history of recurrent UTIs (≥ 3 episodes in previous 12 months).
3. Patient has used antibiotics within the past 7 days from the baseline/screening visit.
4. Patient diagnosed with neurogenic LUTD (i.e., one or more of these conditions: normal-pressure hydrocephalus, cerebral palsy, spinal cord injuries, traumatic brain injury, stroke, Parkinson's disease, multiple sclerosis, meningomyelocele, spina bifida, dementia, Guillain-Barre syndrome, and tumors involving the central nervous systems or spine).
5. Patient diagnosed with interstitial cystitis (IC), bladder pain syndrome, painful bladder syndrome or any etiology of chronic pelvic pain syndrome (CPPS).
6. Patient with a urostomy.
7. Patient with a colostomy.
8. Patient has an atypical anatomic structural variation or has had a previous surgical intervention that has permanently changed structural anatomy anywhere along their lower urinary tract (urethra, pelvic floor, urethral sphincter, and/or bladder wall) that the principal investigator deems might compromise the placement or retention of the Glean sensors during the study (e.g., strictures).
9. Patient has a Pelvic Organ Prolapse Quantification (POP-Q) of Grade III or higher (i.e., most distal portion of the prolapse protrudes more than 1 centimeter below the hymen).
10. Patient with any abnormal or concerning rectal conditions such as ongoing anal fissures, rectocele, fistula, active herpes, or active yeast infections.
11. Patient has a known inability to void.
12. Patient has a previous history of radiation leading to bleeding (e.g., hemorrhagic radiation cystitis).
13. Patient is pregnant (as confirmed by urine pregnancy test or medical history) or breastfeeding, pregnant within the past 6 months, or intending to become pregnant during the study period.
14. Patients who may not be able to independently use a smart device.
15. Subjects who, at the principal investigator's determination, would not be appropriate for this study.

About the study

A prospective, open-label, single arm interventional trial evaluating the safety and performance of the in-clinic and extended monitoring of the lower urinary tract using the Glean Urodynamics System.

What is being tested

Sponsor: Bright Uro · Participants: 101 · Started: Feb 17, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07425015

Locations in the U.S.

LouisianaOchsner Clinic Foundation Research, New Orleans
MarylandChesapeake Urology Associates, Hanover
Chesapeake Urology Associates, Owings Mills
MissouriUrology of St. Louis, St Louis
OhioMetroHealth, Cleveland
South CarolinaSouthern Urogynecology Wellness & Aesthetics, West Columbia
South DakotaSanford Health, Sioux Falls
TexasUrology Partner of North Texas, Arlington
WashingtonSurgical Associates Northwest Urology, Auburn

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.